Wire · opportunities
StemRIM and Shionogi Announce Topline Results of Clinical Trials of Redasemtide in ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
Shionogi and StemRIM announced Phase 2 trial results for redasemtide, showing it met primary endpoints for wound closure in dystrophic epidermolysis bullosa but did not achieve statistical significance in acute ischemic stroke trials. Safety and tolerability were favourable in both indications, and further development decisions are underway.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
You face an opening in rare disease treatment as redasemtide shows promise in epidermolysis bullosa with good safety data. Acute stroke results pause progress there, but focus your attention on rare diseases where unmet need meets early clinical validation.
◆ Coverage
1 source · 9 Sep 2026
◆ Related on Wire
◆ Topics